Aptorum Group and DiamiR Biosciences Advance Merger, Launch Alzheimer's Biomarker Collaboration with AlzLabs
核心洞察
Aptorum Group shareholders approved the all-stock merger with DiamiR Biosciences on June 9, 2026, with the transaction expected to close before fiscal 2027.
The combined company will be renamed Niki BioSolutions, Inc., integrating DiamiR's proprietary microRNA-based diagnostic platform for brain health.
DiamiR announced a collaboration with AlzLabs Precision Diagnostics (搜索) to evaluate blood-based biomarker panels, including p-Tau 217 (搜索) and amyloid 42/40 (搜索), for Alzheimer's disease (搜索).
Aptorum Group Limited (搜索) (NASDAQ: APM) and DiamiR Biosciences Corp. (搜索) have cleared a critical milestone toward completing their all-stock merger, with shareholders of both companies voting to approve the transaction on June 9, 2026. The merger, originally announced on July 16, 2025, will see DiamiR become a wholly owned subsidiary of Aptorum Group, with the combined entity set to be renamed Niki BioSolutions, Inc. upon closing, which is expected before fiscal 2027.
Ian Huen, Chief Executive Officer and Chairman of Aptorum Group, stated, "We are pleased that shareholders of both companies have recognized the strategic rationale and long-term value potential of this transaction. The approval marks an important step in bringing together two innovative companies within the healthcare space."
Alidad Mireskandari, Ph.D., Chief Executive Officer of DiamiR, added, "We are grateful for the strong support demonstrated by shareholders of both organizations. This approval reflects confidence in our strategy to advance innovative diagnostic solutions for neurodegenerative and other brain health and aging related diseases."
DiamiR and AlzLabs Launch Alzheimer's Biomarker Collaboration
In a parallel development announced on June 22, 2026, DiamiR revealed a collaboration with AlzLabs Precision Diagnostics (搜索) to generate protein and microRNA blood-based biomarker data focused on Alzheimer's disease (搜索). The study will measure blood biomarkers of neurodegeneration — including p-Tau 217 (搜索), amyloid 42/40 (搜索), neurofilament light (NfL) (搜索), and other analytes — in well-characterized blood plasma samples collected from study participants whose amyloid status was determined by amyloid PET, the current gold standard.
"Blood biomarkers have emerged as highly promising signature molecules of various stages of Alzheimer's disease (搜索)," said Mireskandari. "Our objective is to evaluate these biomarker panels as standalone tests and in combination with DiamiR's proprietary microRNA platform technology, CogniMIR (搜索)."
The longer-term goal, according to Mireskandari, is "to offer a broad range of non-invasive brain health biomarkers for clinical testing and biopharma services in our CLIA-certified, CAP-accredited clinical laboratory to deliver a more comprehensive assessment of neuropathology to clinicians, clinical researchers, and patients."
Platform Technologies and Strategic Rationale
DiamiR's proprietary platform technology, protected by over 50 issued patents worldwide, is based on quantitative analysis of organ-enriched — including brain-enriched and inflammation-associated — microRNA signatures in plasma. The technology is designed for screening, patient stratification, as well as disease progression and treatment monitoring. DiamiR also offers protein and genetic biomarker analyses through its CLIA-certified, CAP-accredited laboratory.
AlzLabs Precision Diagnostics (搜索) brings a proprietary biomarker panel that provides objective, biologically grounded insights into underlying neurodegenerative processes associated with cognitive decline and brain health. The company focuses on analytical rigor and longitudinal tracking to support earlier understanding of neurobiological change.
Aptorum Group, for its part, is a clinical-stage biopharmaceutical company focused on therapeutic assets in oncology — including orphan oncology indications — and infectious diseases. The merger with DiamiR represents a strategic expansion into molecular diagnostics for brain health.
The completion of the merger remains subject to the satisfaction or waiver of remaining customary closing conditions described in the merger agreement. The registration statement on Form S-4 (File No. 333-290742) was declared effective by the SEC on May 13, 2026, and notice of the shareholder meeting was mailed to Aptorum shareholders on May 20, 2026.